Search

Non-adherence to medication significantly affects bipolar disorder outcomes. Long-Acting Injectable antipsychotics show promise by ensuring adherence and averting relapses. This narrative review sought to evaluate the efficacy of second-generation injectable antipsychotics in bipolar disorder through searches in Embase, MEDLINE, and PsycInfo for randomized controlled trials and mirror-image studies. Risperidone and aripiprazole Long-Acting Injectables demonstrated effectiveness in preventing mood recurrences compared to placebos in adults with bipolar disorder. They showed superiority in preventing mania/hypomania relapses over placebos but did not appear to significantly outperform active oral controls. Notably, active controls seem to be more effective in preventing depression relapses than Long-Acting Injectables. Mirror-Image studies point toward the reduction of hospitalization rates following LAI initiation. The available evidence points thus toward the efficacy of LAIs, especially in managing manic episodes and reducing hospitalizations, The current evidence does not however immediately support prioritizing LAIs over oral medications in bipolar disorder treatment. More high-quality studies, especially comparing LAIs directly with active controls, are crucial to gain a comprehensive understanding of their efficacy. These findings highlight the need for further research to guide clinicians in optimizing treatment strategies for bipolar disorder. [ABSTRACT FROM AUTHOR]

AbstractSubstance use is a significant factor associated with new arrests, detentions and compulsory admissions for patients in forensic assertive community teams (FACT). To enhance community tenure for forensic patients and facilitate their sustainable integration into society, a treatment that offers a community-based alternative to admission following substance use was developed. In this paper, the development of the project, FENIX + is described along with the reporting of a pilot study of all included patients during 12 months (N = 24). Recidivism risk and community integration were assessed utilizing the Short-Term Risk Assessment and Treatability (START) as well as the Measurements in Addiction for Triage and Evaluation (MATE) scales. The included patients avoided 60% of admissions, exhibited positive changes in their desire for assistance, and successfully reduced their risk of recidivism. By accessing the community-based alternative, they were able to delay admissions effectively. These promising results suggest that a community-based treatment could benefit patients at risk of reoffending following substance use. [ABSTRACT FROM AUTHOR]